SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023
January 17, 2023 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Phil...
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022
November 03, 2022 16:05 ET
|
SIGA Technologies Inc.
- Approximately $61 Million of International Sales in the Third Quarter – - Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies,...
SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results
October 27, 2022 16:15 ET
|
SIGA Technologies Inc.
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox
October 12, 2022 16:05 ET
|
SIGA Technologies Inc.
Trials are currently underway in the United States, United Kingdom and Democratic Republic of CongoPending positive results from clinical trials, SIGA plans to file with U.S. regulators for regulatory...
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®
September 29, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the...
SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)
September 26, 2022 10:07 ET
|
SIGA Technologies Inc.
- Order for Approximately $10 Million Funded by the European Commission – - Orders for Approximately $6 Million Received from Two Countries in the Asia Pacific Region - NEW YORK, Sept. 26,...
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
August 09, 2022 07:30 ET
|
SIGA Technologies Inc.
- IV TPOXX is an Important Option for Those Unable to Swallow – - Option to Fund Post-Marketing Field Study for IV TPOXX also Exercised – NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SIGA...
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022
August 04, 2022 16:05 ET
|
SIGA Technologies Inc.
- Approximately $9 Million of Product Sales in the Second Quarter, including First Oral TPOXX® Sale to the U.S. Department of Defense and Approximately $5 Million of International Sales – - Received...
SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results
July 28, 2022 16:15 ET
|
SIGA Technologies Inc.
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...